Newsfile Corp
23 Aug 2026, 10:27 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An FDA advisory committee (AdCom) voted 9-3 that available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy. — A strong negative vote from an FDA advisory panel significantly reduces the likelihood of drug approval, which is a primary value driver for biotech firms.
-0.90The FDA released briefing documents stating the benefit-risk assessment for deramiocel appeared unfavorable due to a lack of evidence of effectiveness. — Direct negative feedback from the regulator regarding the core product's benefit-risk profile is a critical negative catalyst.
-0.80Capricor Therapeutics is facing a federal securities class action lawsuit alleging it misled investors regarding the regulatory prospects of deramiocel. — Litigation introduces legal liability and potential financial settlements, adding risk overhead to the company.
-0.40Continue reading
6 related stories
Search tags
The lawsuit alleges Capricor changed its clinical data statistical analysis plan without prior FDA agreement before resubmitting its Biologics License Application (BLA). — Allegations of improper regulatory conduct suggest mismanagement and increase the probability of a formal FDA rejection.
-0.30Which stocks this story touches
The company is facing a securities class action lawsuit following significant stock price drops and negative FDA feedback regarding the efficacy of its drug Deramiocel.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
18h ago
